Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 19/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 17/20 | 0.69 |
| ▸ | PDE4A | P27815 | 11/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21750050 | 0.91 | PDE4B (0.68) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL21750048 | 0.91 | PDE4B (0.68) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1193538 | 0.89 | PDE4B (0.78) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL15198844 | 0.89 | PDE4B (0.78) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL29651471 | 0.89 | PDE4B (0.78) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL17266336 | 0.87 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1194579 | 0.86 | PDE4B (0.74) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL23926412 | 0.85 | PDE4B (0.65) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL23499804 | 0.85 | PDE4B (0.65) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL31063328 | 0.85 | PDE4B (0.65) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1698334-B1 | Pharmaceutically active isoindoline derivatives | CELGENE CORP (US) | 2011-04-20 | — | — | EP | claimed |
| EP-1778635-A2 | ISOINDOLINE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CELGENE CORPORATION (US) | 2007-05-02 | — | — | EP | claimed |
| EP-1698334-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2006-09-06 | — | — | EP | claimed |
| US-20060084815-A1 | Isoindoline compounds and methods of making and using the same | AMGEN INC. | 2006-04-20 | — | — | US | claimed |
| WO-2006025991-A2 | ISOINDOLINE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CELGENE CORPORATION (US) | 2006-03-09 | — | — | WO | claimed |
| EP-2555769-B1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | AMGEN EUROPE GMBH (CH) | 2022-01-12 | — | — | EP | disclosed |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | AMGEN INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180318257-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | CELGENE CORPORATION | 2018-11-08 | — | — | US | disclosed |
| EP-2583098-B1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORP (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2583098-B1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORP (US) | 2018-08-08 | — | — | EP | disclosed |
| WO-2017070291-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | CELGENE CORPORATION (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070291-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | CELGENE CORPORATION (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20050239867-A1 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension | CELGENE CORPORATION | 2005-10-27 | — | — | US | disclosed |
| WO-2005094218-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CELGENE CORPORATION (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050142104-A1 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders | CELGENE CORPORATION | 2005-06-30 | — | — | US | disclosed |
| WO-2005046592-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERS | CELGENE CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005043971-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF PAIN | CELGENE CORPORATION (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005044269-A1 | CYTOKINE INHIBITORY DRUGS FOR TREATMENT OF MACULAR DEGENERATION | CELGENE CORPORATION (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20040147588-A1 | Pharmaceutically active isoindoline derivatives | MAN HON-WAH | 2004-07-29 | — | — | US | disclosed |
| US-6667316-B1 | Amido or imido functionality; tumor necrosis factor alpha, phosphodiesterases, matrix metalloproteases and angiogenesis inhibitors | CELGENE CORPORATION | 2003-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050142104-A1 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4C 8/4885PDE4A 1/4885 |
| US-20050239867-A1 | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4C 8/4885PDE4A 1/4885 |
| US-20040147588-A1 | Pharmaceutically active isoindoline derivatives | PDE3A, PDE5A, PDE2A | PDE4B 14/4885PDE4C 10/4885PDE4A 6/4885 |
| US-20180318257-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4C 5/4885PDE4A 1/4885 |
| US-10682336-B2 | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4C 5/4885PDE4A 1/4885 |
| US-20060084815-A1 | Isoindoline compounds and methods of making and using the same | MCL1, HPGDS, TPMT | PDE4B 1194/4885PDE4C 1258/4885PDE4A 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.